Fundraising Fox
/Companies
Sign in

Verax Biomedical

Marlborough, US · 1 known investors

Find your way into Verax Biomedical

Sign up to see every warm intro you have to Verax Biomedical

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Verax Biomedical team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Verax Biomedical develops rapid bacterial contamination detection tests for blood products and tissues intended for transfusion and transplantation. The company serves blood banks, hospitals, and transfusion centers seeking to prevent infectious complications from bacterial growth in stored cellular materials.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

JR
JOE R. SANDERSChief Marketing & Business Development Officer
YRYLI REMO VALLEJO
YLI REMO VALLEJOSenior Vice President, Research & DevelopmentYlli Remo Vallejo is an Executive Officer at Verax Biomedical who previously led research and product development teams in medical diagnostics, drugs of abuse testing, and biothreat detection, with expertise in regulatory compliance and multiple FDA product clearances. He holds seven awarded patents and has published work in pesticide immunodetection and immunogenicity testing.
RS
R. SCOTT MCKENZIE, SR.Sr. VP Operations
NA
NANCY A. HORNBAKERVice President Regulatory Affairs
PR
PAUL RAGUSAVice President

Board

MGMARC GOLDBERG
MARC GOLDBERGBoard directorCo-Founder and Managing Partner at Bioventures Investors
JL
JAMES LOUSARARIANBoard director
JD
JOE DEL GUERCIOBoard director
JK
JAMES KOZIARZBoard director
RZ
ROBERT ZIESERLBoard director
BB
BUZZ BENSONBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$30.6M disclosed across 4 of 5 rounds · 2013–2019

▶$2.5MraisedSep 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James LousararianExecutive Officer, Director
  • Paul RagusaExecutive Officer
  • Joe SandersDirector
  • Robert FlanaganDirector
  • Marc GoldbergDirector
Offering amount
$10.5M
Amount sold
$2.5M
Sales commissions
$425K
Placement agents
Thomas Frederick Zipser
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.4MraisedNov 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES LOUSARARIANExecutive Officer, Director
  • JOE SANDERSExecutive Officer, Director
  • MARC E. GOLDBERGDirector
  • JOE DEL GUERCIODirector
Offering amount
$24.1M
Amount sold
$11.4M
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.6MraisedJun 2016 · 64 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • PAUL RAGUSAExecutive Officer
  • MARC E. GOLDBERGDirector
  • JAMES KOZIARZDirector
  • JAMES LOUSARARIANExecutive Officer, Director
  • YLI REMO VALLEJOExecutive Officer
  • JOE DEL GUERCIODirector
  • NANCY A. HORNBAKERExecutive Officer
  • JOE R. SANDERSExecutive Officer, Director
  • R. SCOTT MCKENZIEExecutive Officer
Offering amount
$24.5M
Amount sold
$12.6M
First sale
Feb 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJan 2015 · 61 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES KOZIARZDirector
  • JOE R. SANDERSExecutive Officer, Director
  • ROBERT ZIESERLDirector
  • BUZZ BENSONDirector
  • YLI REMO VALLEJOExecutive Officer
  • R. SCOTT MCKENZIE, SR.Executive Officer
  • NANCY A. HORNBAKERExecutive Officer
  • PAUL RAGUSAExecutive Officer
  • MARC GOLDBERGDirector
  • JAMES LOUSARARIANExecutive Officer, Director
  • JOE DEL GUERCIODirector
Offering amount
$4M
Amount sold
$4M
First sale
Jan 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies working in the same space as Verax Biomedical.

In the news

Verax Biomedical Closes $12MM Funding Round - Verax Biomedicalveraxbiomedical.com · Oct 2013Verax Biomedical, Incorporated Closes $12 Million Funding Round - BioSpacebiospace.com · Oct 2013

Frequently asked questions

What does Verax Biomedical do?
Verax Biomedical develops rapid bacterial contamination detection tests for blood products and tissues intended for transfusion and transplantation. The company serves blood banks, hospitals, and transfusion centers seeking to prevent infectious complications from bacterial growth in stored cellular materials.
Who are Verax Biomedical's investors?
Verax Biomedical's investors include Bioventures Investors.
How much funding has Verax Biomedical raised?
Verax Biomedical has disclosed $30.6M raised across 4 of its 5 known rounds.
Where is Verax Biomedical headquartered?
Verax Biomedical is headquartered in Marlborough, US.